The estimated Net Worth of Ryan David Lake is at least $2.31 Million dollars as of 12 November 2021. Mr. Lake owns over 1,212 units of Recro Pharma Inc stock worth over $782,465 and over the last 7 years he sold REPH stock worth over $0. In addition, he makes $1,529,610 as Chief Financial Officer at Recro Pharma Inc.
Sign up
Mr. Lake REPH stock SEC Form 4 insiders trading
Ryan has made over 4 trades of the Recro Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 1,212 units of REPH stock worth $2,000 on 12 November 2021.
The largest trade he's ever made was exercising 6,000 units of Recro Pharma Inc stock on 27 January 2020 worth over $12,540. On average, Ryan trades about 382 units every 20 days since 2017. As of 12 November 2021 he still owns at least 374,385 units of Recro Pharma Inc stock.
You can see the complete history of Mr. Lake stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ryan Lake biography
Ryan David Lake serves as Chief Financial Officer of the Company. He had previously served as our Senior Vice President of Finance and Chief Accounting Officer since June 2017. Mr. Lake has also served as the Chief Financial Officer of Baudax Bio since the Separation in November 2019. Mr. Lake has over 20 years of senior financial and life sciences leadership experience. Prior to joining us, Mr. Lake served as Chief Financial Officer and Vice President of Finance of Aspire Bariatrics, Inc., a privately-held, commercial-stage, medical device company from July 2015 to May 2017. From 2012 to 2015, Mr. Lake held executive management and senior finance positions, including Director of the Natural Materials Division, Controller and Senior Director of Finance, at DSM Biomedical (successor to Kensey Nash Corporation after its acquisition in 2012), a division of Royal DSM (listed on Euronext Amsterdam), a global science-based company active in health, nutrition and materials. From 2002 to 2012, Mr. Lake held various senior financial positions of increasing responsibility, most notably Senior Director of Finance and Interim Chief Financial Officer, with Kensey Nash Corporation, a medical device company. Earlier in his career, Mr. Lake worked at Deloitte & Touche, LLP. Mr. Lake has a B.S. degree in Accounting from West Chester University of Pennsylvania and is a certified public accountant and Chartered Global Management Accountant.
What is the salary of Ryan Lake?
As the Chief Financial Officer of Recro Pharma Inc, the total compensation of Ryan Lake at Recro Pharma Inc is $1,529,610. There are 1 executives at Recro Pharma Inc getting paid more, with Geraldine Henwood having the highest compensation of $4,622,980.
How old is Ryan Lake?
Ryan Lake is 42, he's been the Chief Financial Officer of Recro Pharma Inc since 2018. There are 9 older and no younger executives at Recro Pharma Inc. The oldest executive at Recro Pharma Inc is Winston Churchill, 79, who is the Independent Director.
What's Ryan Lake's mailing address?
Ryan's mailing address filed with the SEC is C/O RECRO PHARMA, INC., 1 E. UWCHLAN AVE, SUITE 112, EXTON, PA, 19341.
Insiders trading at Recro Pharma Inc
Over the last 11 years, insiders at Recro Pharma Inc have traded over $25,533,136 worth of Recro Pharma Inc stock and bought 3,055,820 units worth $22,429,197 . The most active insiders traders include Healthcare Master Fund Ltd ..., Investment Company, Inc. Awm und James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of $151,953. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth $1,004.
What does Recro Pharma Inc do?
Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
What does Recro Pharma Inc's logo look like?
Complete history of Mr. Lake stock trades at Recro Pharma Inc und Baudax Bio Inc
Recro Pharma Inc executives and stock owners
Recro Pharma Inc executives and other stock owners filed with the SEC include:
-
Geraldine Henwood,
President, Chief Executive Officer, Director -
Ryan Lake,
Chief Financial Officer -
William Ashton,
Independent Director -
Wayne Weisman,
Independent Chairman of the Board -
Winston Churchill,
Independent Director -
Michael Berelowitz,
Independent Director -
Ryan D. Lake,
Chief Financial Officer -
Bryan Reasons,
Independent Director -
J. David Enloe Jr.,
Pres, CEO & Director -
Argot Partners,
IR Contact Officer -
Tim Bourque,
VP of Operations & Site Head of San Diego -
David Smithwick B.S.,
VP of Operations & Site Head of Gainesville -
Richard Sidwell Ph.D.,
VP & Chief Scientific Officer -
Marshall Rizzo M.B.A.,
Sr. VP & GM -
Randall J. Mack,
Sr. VP of Devel. -
Erica Raether M.A.,
VP of People, Culture & ESG -
William Hirschman,
VP of Sales & Marketing -
Matthew McKendry,
Director of Accounting -
Laura L. Parks,
Director -
Karen Flynn,
Director -
Vitalife Partners Ii Lp Scp,
10% owner -
Donna Nichols,
CAO/Controller -
Stewart Mc Callum,
Chief Medical Officer -
Randall Mack,
Senior VP, Development -
Fred Graff,
Chief Commercial Officer -
Capital Management, Llc Sto...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Vitalife Partners (Israel) ...,
10% owner -
Alfred Altomari,
Director -
Healthcare Master Fund Ltd ...,
-
Diane Myers,
Senior VP-Reg./Quality -
Jyrki Mattila,
Executive VP, Business Dev. -
Michael Celano,
Chief Financial Officer -
Arnaud Ajdler,
Director -
Abraham Ludomirski,
Director -
Charles Garner,
CFO and Chief Business Officer -
J David Jr Enloe,
Chief Executive Officer -
James Charles Miller,
Director -
Investment Company, Inc. Awm,
10% owner